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ABSTRACT
Objectives To determine the prevalence of comorbidities 
in patients with type 2 diabetes mellitus (T2DM) and 
identify the factors independently associated with 
comorbidities in a tertiary care department in Ningbo, 
China.
Design A computerised medical records database was 
used to conduct a cross- sectional study.
Setting The study was conducted in a tertiary care 
department in Ningbo, China.
Participants The study was conducted on adult patients 
with T2DM, and it included 8 years of data, from 1 January 
2012 to 31 December 2019.
The primary outcome measure Comorbidity was defined 
as the coexistence of at least one other chronic condition, 
that is, either a physical non- communicable disease 
(duration ≥3 months), a mental health condition (duration 
≥3 months) or an infectious disease (duration ≥3 months).
Results In total, 4777 patients with T2DM satisfied the 
eligibility criteria. Over 8 years, the prevalence of comorbidities 
was 93.7%. The odds of comorbidities increased with the age 
of patients (18 to 39 years: 1; 40 to 59 years: OR 2.80, 95% 
CI 1.98 to 3.96; 60 to 69 years: OR 4.43, 95% CI 3.04 to 6.44; 
and ≥70 years: OR 10.97, 95% CI 7.17 to 16.77). The odds 
were lower in female patients (OR 0.66, 95% CI 0.51 to 0.84), 
patients residing in rural areas (OR 0.75, 95% CI 0.59 to 0.95) 
and patients without health insurance (OR 0.62, 95% CI 0.46 
to 0.83). The odds were higher in single/divorced/widowed 
patients compared with those in married patients (OR 1.95, 
95% CI 1.21 to 3.12).
Conclusions A large percentage of patients with T2DM in the 
tertiary care department in Ningbo, China, had comorbidities, 
and the factors associated with comorbidities were identified. 
The findings could be used in developing, evaluating and 
implementing interventions aimed at improving outcomes in 
patients with T2DM with comorbidities.
INTRODUCTION
Ningbo is an economically developed 
Chinese city in Zhejiang Province. The 
population of the city is approximately 
8.2 million.1 Non- communicable diseases are 
prevalent in the city, and one of the most 
prevalent non- communicable diseases is 
type 2 diabetes mellitus (T2DM), a complex 
metabolic disorder.2 China has the largest 
T2DM epidemic in the world, and in Ningbo, 
its prevalence in adults ≥40 years of age 
is 21%.3 In Ningbo, the diabetes- related 
mortality is 14.5 per 100 000 population.4
There is no international consensus 
regarding the best way to define comorbidity. 
It is usually defined as the coexistence of 
other conditions with an index condition (ie, 
the main condition under study) where these 
other conditions are not consequences of 
the index condition.5–7 Comorbidities accel-
erate the progression of individual condi-
tions, encourage the development of other 
physical and mental conditions and even 
lead to premature mortality.8–10 Moreover, 
they negatively affect overall health, well- 
being and functioning.11 12 Additionally, they 
lead to high treatment burden, high health-
care utilisation and expenditure and loss of 
economic output.13 14 In real life, T2DM is 
rarely presented in isolation and is always 
accompanied by comorbidity.15 16
Strengths and limitations of this study
 ► Ours was the first study to investigate comorbidities 
in patients with type 2 diabetes in Ningbo and the 
broader Zhejiang Province of China.
 ► We included all the chronic conditions in our 
study; they were coded using the International 
Classification of Diseases, 10th edition (ICD-10) in 
our database.
 ► Our study had extremely low missing data, and the 
multiple logistic regression analysis included a sam-
ple with missing data for the adjusted variable.
 ► As it was a cross- sectional study, the causal rela-
tionship between the variables and the comorbidi-
ties could not be determined.
 ► The high prevalence of comorbidities in our study 
could be due to the study setting (ie, hospital).









pen: first published as 10.1136/bm




2 Li X, et al. BMJ Open 2021;11:e040532. doi:10.1136/bmjopen-2020-040532
Open access 
To date, no study has been undertaken to investigate 
comorbidities in patients with T2DM in Ningbo. The 
study objectives were to determine the prevalence of 
comorbidities in patients with T2DM and identify the 
factors independently associated with comorbidities. 
This knowledge could be used in developing, evaluating 
and implementing interventions aimed at improving 
outcomes in patients with T2DM with comorbidities.
METHODS
Study location, study design, data source and study period
We conducted the study in a tertiary care department, the 
Department of Endocrinology and Metabolism, Ningbo 
First Hospital, in Ningbo, China. This tertiary care 
hospital delivers speciality healthcare services, provides 
medical education and conducts research.17 18 Locals and 
people from the surrounding areas visit this hospital as 
no referral is required from the general practitioner.17 
An existing computerised medical records database was 
used for conducting this cross- sectional study. This data-
base contained information on all inpatients. Since it was 
a real- time database, new patients were added continu-
ously. Data were entered by the medico- nursing team, and 
an independent group of the hospital staff was respon-
sible for assessing the quality of the data and overall data-
base management. All the conditions were coded using 
the International Classification of Diseases, 10th edition 
(ICD-10). This retrospective study included 8 years of 
data, from 1 January 2012 to 31 December 2019, and the 
information was available on 6755 patients.
Study population and study inclusion and exclusion criteria
Adult patients (≥18 years) with T2DM were included. 
If a patient was admitted more than once during the 
study period, data pertinent to the last admission were 
extracted to obtain the most recent information on 
health conditions. Individuals with gestational diabetes, 
type 1 diabetes, secondary diabetes and unknown types of 
diabetes were excluded.
Study variables
We extracted and categorised the following information 
from the database:
 ► age (18 to 39 years, 40 to 59 years, 60 to 69 years or 
≥70 years),
 ► sex (male or female),
 ► education (university/college, class 7 to 12, class 1 to 
6 or no qualification),
 ► occupation (manual worker (ie, more physical work 
than mental work), non- manual worker (ie, more 
mental work than physical work) or never worked/
retired),
 ► marital status (married or single/divorced/widowed),
 ► residence (urban or rural using the ‘hukou’ system 
that is, the Chinese household registration system),
 ► health insurance,
 ► smoking (current status),
 ► alcohol consumption (current status),
 ► duration of T2DM (≤1 year, >1 to 5 years, >5 to 10 
years or >10 years) and
 ► blood glucose level (glycated haemoglobin (HbA1c 
<7% (good) or ≥7% (poor)), estimated using the 
high- performance liquid chromatographic method 
and D-10 Haemoglobin Analyser (Bio- Rad, USA)). 
In China, the recommended HbA1c treatment target 
did not change over the study period (<7% for most 
patients with T2DM).19–21
In addition, information on comorbidities was 
extracted. The index condition was T2DM. Comor-
bidity was defined as the coexistence of at least one 
other chronic condition, that is, either a physical non- 
communicable disease (duration ≥3 months), a mental 
health condition (duration ≥3 months) or an infectious 
disease (duration ≥3 months).5–7 T2DM- specific compli-
cations (ie, microvascular complications, such as diabetic 
retinopathy, nephropathy and neuropathy/foot) were 
excluded as these were consequences of the index condi-
tion; hence, they were not considered as comorbidities.6
The researchers had no access to information that 
could identify individual patients during data analyses. No 
informed consent was required as per the research ethics 
rules.
Patient and public involvement
Patients and the public were not involved in the study.
Statistical analyses
We calculated numbers and percentages for categorical 
variables and means and SDs for normally distributed 
continuous variables. We used simple logistic regres-
sion method to investigate the association between the 
different variables and the comorbidities. We developed 
a multiple logistic regression model to identify any inde-
pendent associations. For this, we used backward step-
wise regression analysis and included all the variables. 
Additionally, we performed a sensitivity analysis—in the 
multiple logistic regression model, we included only those 
variables that had a p value≤0.20 in simple logistic regres-
sions. We calculated ORs and 95% CIs. We used IBM SPSS 
Statistics V.26.0 for Windows for statistical analyses.
RESULTS
A total of 4777 patients with T2DM satisfied the eligibility 
criteria. The mean (±SD) age of patients was 64.2 (±14.2) 
years, and approximately 52% (n=2482) of them were men. 
The mean (±SD) HbA1c level was 9.2% (±2.4%). Over 
8 years, the prevalence of comorbidities was 93.7%. The 
year- wise prevalences from 2012 to 2019 were 96.9%, 95.0%, 
92.9%, 95.5%, 93.2%, 91.5%, 94.0% and 93.6%, respectively.
Figure 1 shows the number of comorbidities in our 
study. The mean (±SD) number of comorbidities was 3 
(±1). Figure 2 shows the percentage of comorbidities in 
our study in the different age groups. In the ≥70 years 
age group, 68.5% (1247) had ≥3 comorbidities, whereas 
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the prevalences were only 33.1% (102), 43.5% (592) and 
55.5% (715) in the 18 to 39, 40 to 59 and 60 to 69 years age 
groups, respectively. Table 1 reports the most common 
comorbidities in our study. Essential hypertension 
(49.4%), disorders of lipoprotein metabolism and other 
lipidaemias (33.7%), non- toxic thyroid nodule (22.8%), 
fatty change of liver (20.6%) and cataract (10.7%) were 
the five most prevalent comorbidities.
Table 2 reports the characteristics of the study partici-
pants. We found that the comorbidities were associated 
with age, sex, education, occupation, marital status, 
residence, health insurance and the duration of T2DM. 
Table 3 reports the multiple backward stepwise logistic 
regression analysis for determining factors independently 
associated with the comorbidities. The odds of comorbid-
ities increased with the age of patients (18 to 39 years: 
1; 40 to 59 years: OR 2.80, 95% CI 1.98 to 3.96; 60 to 69 
years: OR 4.43, 95% CI 3.04 to 6.44; and ≥70 years: OR 
10.97, 95% CI 7.17 to 16.77). The odds were lower in 
female patients (OR 0.66, 95% CI 0.51 to 0.84), patients 
residing in rural areas (OR 0.75, 95% CI 0.59 to 0.95) 
and patients without health insurance (OR 0.62, 95% CI 
0.46 to 0.83). The odds were higher in single/divorced/
widowed patients compared with married patients (OR 
1.95, 95% CI 1.21 to 3.12). We obtained similar results in 
the sensitivity analysis.
DISCUSSION
In our tertiary care department in Ningbo, China, 
approximately 94% of the patients with T2DM had 
comorbidities, and this influenced the overall manage-
ment. In a previous study, we found that approximately 
72% of the patients with T2DM were prescribed poly-
pharmacy.22 There are no similar studies on comorbidi-
ties conducted in patients with T2DM in China published 
in the English language. However, we found two similar 
studies published in Mandarin: one on patients with 
diabetes at a community health centre and another on 
outpatients with T2DM at a tertiary care hospital.23 24 The 
corresponding prevalence figures were around 95% and 
73%, respectively. The different prevalence figures could 
be explained by the differences in population charac-
teristics, the study setting and the definition of comor-
bidity applied. Several studies have been conducted on 
this subject in high- income countries, such as the USA 
and European countries.25–29 All these studies, and also 
our study, have highlighted the fact that comorbidities 
are highly prevalent in patients with T2DM. A systematic 
Figure 1 Number of comorbidities in our study. T2DM, type 
2 diabetes mellitus.
Figure 2 Percentage of comorbidities in our study in the 
different age groups. T2DM, type 2 diabetes mellitus.
Table 1 Most common comorbidities in our study





Essential hypertension (I10) 2362 (49.4)
Disorders of lipoprotein metabolism and 
other lipidaemias (E78)
1612 (33.7)
Non- toxic thyroid nodule (E04) 1088 (22.8)
Fatty (change of) liver (K76) 984 (20.6)
Cataract (H26) 512 (10.7)
Chronic ischaemic heart disease (I25) 455 (9.5)
Atherosclerosis (I70) 411 (8.6)
Osteoporosis (M81) 348 (7.3)
Cerebral infarction (I63) 341 (7.1)
Benign prostatic hyperplasia (N40) 303 (12.2*)
Abnormal findings on diagnostic imaging of 
lung (R91)
287 (6.0)
Thoracic, thoracolumbar and lumbosacral 
intervertebral disc disorders (M51)
260 (5.4)
Obesity (E66) 177 (3.7)
Cervical disc disorders (M50) 161 (3.4)
Chronic viral hepatitis (B18) 138 (2.9)
Sleep disorders (G47) 135 (2.8)
Gout (M10) 132 (2.8)
Disorders of purine and pyrimidine 
metabolism (E79)
127 (2.7)
Atrial fibrillation and flutter (I48) 118 (2.5)
Gastro- oesophageal reflux disease (K21) 111 (2.3)
*In 2482 men.
ICD-10, International Classification of Diseases, 10th edition; 
T2DM, type 2 diabetes mellitus.
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(95% CI) P value
Age (years) <0.001
  18–39 308 63 (20.5) 245 (79.5) 1
  40–59 1360 120 (8.8) 1240 (91.2) 2.66 (1.90 to 3.71)
  60–69 1289 75 (5.8) 1214 (94.2) 4.16 (2.90 to 5.98)
  ≥70 1820 41 (2.3) 1779 (97.7) 11.16 (7.37 to 16.90)
Sex 0.008
  Male 2482 133 (5.4) 2349 (94.6) 1
  Female 2295 166 (7.2) 2129 (92.8) 0.73 (0.57 to 0.92)
Education 0.005
  University/college 545 47 (8.6) 498 (91.4) 1
  Class 7–12 1927 136 (7.1) 1791 (92.9) 1.24 (0.88 to 1.76)
  Class 1–6 1574 80 (5.1) 1494 (94.9) 1.76 (1.21 to 2.56)
  No qualification 731 36 (4.9) 695 (95.1) 1.82 (1.16 to 2.86)
Occupation <0.001
  Manual worker 1088 74 (6.8) 1014 (93.2) 1
  Non- manual worker 1884 152 (8.1) 1732 (91.9) 0.83 (0.62 to 1.10)
  Never worked/retired 1805 73 (4.0) 1732 (96.0) 1.73 (1.24 to 2.41)
Marital status 0.008
  Married 4207 278 (6.6) 3929 (93.4) 1
  Single/divorced/widowed 570 21 (3.7) 549 (96.3) 1.85 (1.18 to 2.91)
Residence <0.001
  Urban 2815 145 (5.2) 2670 (94.8) 1
  Rural 1962 154 (7.8) 1808 (92.2) 0.64 (0.50 to 0.81)
Health insurance <0.001
  Yes 4211 232 (5.5) 3979 (94.5) 1
  No 564 67 (11.9) 497 (88.1) 0.43 (0.33 to 0.58)
Smoking (current status) 0.073
  No 3714 245 (6.6) 3469 (93.4) 1
  Yes 1063 54 (5.1) 1009 (94.9) 1.32 (0.98 to 1.79)
Alcohol consumption (current status) 0.713
  No 4169 263 (6.3) 3906 (93.7) 1
  Yes 608 36 (5.9) 572 (94.1) 1.07 (0.75 to 1.53)
Duration of T2DM (years) <0.001
  ≤1 981 93 (9.5) 888 (90.5) 1
  >1–5 880 60 (6.8) 820 (93.2) 1.43 (1.02 to 2.01)
  >5–10 1247 74 (5.9) 1173 (94.1) 1.66 (1.21 to 2.28)
  >10 1669 72 (4.3) 1597 (95.7) 2.32 (1.69 to 3.19)
Blood glucose level (HbA1c) 0.458
  <7% 899 64 (7.1) 835 (92.9) 1
  ≥7% 3748 226 (6.0) 3522 (94.0) 1.19 (0.90 to 1.59)
  Unknown 130 9 (6.9) 121 (93.1) 1.03 (0.50 to 2.12)
HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus.
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review and meta- analysis of the prevalence of comorbidi-
ties in patients with T2DM in different geographical loca-
tions and the factors associated with it will be helpful.
Comorbidities are not synonymous with complica-
tions.6 In a previous study on the vascular complications 
of T2DM, we included microvascular complications (ie, 
diabetic retinopathy, nephropathy and neuropathy/
foot) and macrovascular complications (ie, coronary 
heart disease, stroke and peripheral arterial disease) 
and found that more than one- half of the patients with 
T2DM had vascular complications.30 In the present study, 
we explored comorbidities in patients with T2DM using 
a recommended definition. Comorbidity was defined as 
the coexistence of at least one other chronic condition, 
either a physical (non- communicable/infectious disease) 
or mental health condition.5–7 Unlike the previous study, 
in the present study, microvascular complications were 
excluded, as these were consequences of T2DM and 
should not be considered as comorbidities.6 Although 
HIV infection, tuberculosis and mental health conditions 
are common comorbidities in patients with T2DM,31–34 
these were not the most common comorbidities in this 
study. The prevalences of these infectious diseases are low 
in Ningbo,35–38 and there are chances that mental health 
conditions were under- reported. It should also be noted 
that infectious diseases and mental health conditions as 
index conditions are treated in other specialised hospitals 
in Ningbo.
We found that the odds of comorbidities increased 
with age in patients with T2DM. Age is one of the most 
well- studied and consistent determinants of comorbid-
ities.25 28 39 Age- related organ degeneration is a natural 
process and can lead to the development of many health 
conditions.40 However, it should be noted that comorbid-
ities do not correspond with age, and they are not limited 
to the older population alone.41 In our study, the prev-
alences of comorbidities were around 80% and 91% in 
the 18 to 39 and 40 to 59 years age groups, respectively. 
We found that the odds of comorbidities were lower in 
female patients with T2DM compared with those in their 
male counterparts. This finding is consistent with other 
studies.25 28 This could be due to differences at the biolog-
ical level. Another potential reason could be the reporting 
differences in sex- specific health conditions. For example, 
female patients with T2DM often present with atypical 
symptoms of cardiovascular diseases.42 Additionally, the 
standard non- invasive diagnostic tests perform better in 
men than in women.43 All these hinder the diagnosis of 
cardiovascular diseases in women. Another example is 
benign prostatic hyperplasia, one of the most common 
comorbidities in our study. This comorbidity was diag-
nosed because of the compulsory ultrasound scan of the 
urinary system of patients with T2DM at our hospital for 
possible kidney diseases. In comparison, the gynaecolog-
ical examination is not a routine examination in women 
with T2DM.
We found that the odds of comorbidities were lower 
in patients with T2DM residing in rural areas compared 
with those in urban areas. This could be due to economic 
growth, urbanisation and its negative consequences, 
such as an unhealthy lifestyle.44–46 The link between an 
unhealthy lifestyle and chronic conditions (particu-
larly non- communicable diseases) is well established.47 
A similar association has also emerged with comorbidi-
ties.23 48 Another reason could be that rural patients in 
China have limited access to healthcare and thus, they may 
undergo fewer diagnostic tests and obtain fewer confir-
mations of health conditions.49 We found that the odds of 
comorbidities were lower in patients with T2DM without 
health insurance compared with those with health insur-
ance. This could be due to the fact that over 90% of the 
Chinese population have some sort of health insurance,50 
and these patients may undergo more diagnostic tests 
(within the scope of their health insurance policy) and 
obtain confirmation of a range of health conditions.51 
We found that the odds of comorbidities were higher in 
single/divorced/widowed patients with T2DM compared 
with those in married patients. In general, the spouses 
of married patients provide both physical and mental 
support to them, and this could help them manage their 
existing health conditions and prevent new ones from 
emerging.52 53
This study has several strengths and weaknesses. 
Comorbidity is a less- explored area in China, and to 
the best of our knowledge, this was the first study to 
explore comorbidities in patients with T2DM in Ningbo 
and the broader Zhejiang Province. The quality of our 
routinely collected data was good. Unlike other studies 
where comorbidities in T2DM were self- reported by 
the patients with T2DM using a predetermined list of 
Table 3 Multiple backward stepwise logistic regression 
analysis for determining factors independently associated 
with comorbidity
Adjusted OR (95% CI) P value
Age (years) <0.001
  18–39 1   
  40–59 2.80 (1.98 to 3.96)   
  60–69 4.43 (3.04 to 6.44)   
  ≥70 10.97 (7.17 to 16.77)
Sex <0.001
  Male 1
  Female 0.66 (0.51 to 0.84)
Marital status 0.006
  Married 1
  Single/divorced/widowed 1.95 (1.21 to 3.12)
Residence 0.018
  Urban 1
  Rural 0.75 (0.59 to 0.95)
Health insurance 0.002
  Yes 1
  No 0.62 (0.46 to 0.83)
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selected comorbidities,23 24 we used a holistic approach. 
All the conditions were coded using the ICD-10 in our 
database, and we included all the chronic conditions in 
our study. This also minimised the possibility of recall 
bias in our study. Our study had extremely low missing 
data; only HbA1c data were missing in 130 patients out 
of 4777 (ie, 2.7%). Multiple logistic regression analysis 
included a sample with missing data for the adjusted 
variable. Since it was a cross- sectional study, the causal 
relationship between the variables and the comorbid-
ities could not be determined. We propose to conduct 
a longitudinal study to explore the effects of various 
factors on comorbidities, including factors considered in 
this study and other factors, such as physical activity and 
diet that were not present in our database and could not 
be adjusted for in the models. In our study, the high prev-
alence of comorbidities could be due to the study setting 
(ie, hospital). The findings of our hospital- based study 
could be valid in similar settings. We suggest conducting 
a population- based study that might provide a distinct 
picture of the issue in Ningbo.
In conclusion, we found that a large percentage of 
patients with T2DM in the tertiary care department in 
Ningbo, China, had comorbidities, and we also identified 
the factors associated with comorbidities. The findings 
could be used in developing, evaluating and imple-
menting interventions aimed at improving outcomes in 
patients with T2DM with comorbidities.
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